Navigation Links
New Review of Novel Intranasal Delivery of Sumatriptan as a Route to Rapid and Sustained Relief in the Acute Treatment of Migraine
Date:11/17/2016

LONDON, November 17, 2016 /PRNewswire/ --

Deborah I Friedman, US Neurology , 2016;12(2):84-9: https://doi.org/10.17925/USN.2016.12.02.84

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)
Published recently in US Neurology, the peer-reviewed journal from touchNEUROLOGY, Deborah I Friedman discusses a new treatment in migraine. This condition remains a common debilitating condition that exerts a high social and economic burden worldwide. Despite the widespread availability of various medications for migraine, many patients are dissatisfied with their treatment. Rapid and effective treatment at an early stage in an attack is vital in migraine to prevent central sensitization leading to attacks that are difficult to treat. Most migraineurs prefer oral medications but this is not always the most rapid or efficient route into the bloodstream. Intranasal administration of migraine treatment provides a rapid, convenient and reliable alternative to oral and other routes. AVP-825 is an intranasal medication delivery system approved by the US Food and Drug Administration in January 2016 as ONZETRA™ Xsail™ (sumatriptan nasal powder [Avanir Pharmaceuticals, Aliso Viejo, CA]) for the acute treatment of migraine with or without aura in adults. AVP-825 contains low dose sumatriptan powder and takes advantage of some unique aspects of the nasal anatomy to confer rapid pain relief in the acute treatment of migraine. In two Phase III trials, AVP-825 was well tolerated and showed significantly faster migraine pain relief and relief from other symptoms including photophobia, phonophobia, and nausea than placebo or oral sumatriptan. This benefit was achieved with substantially lower drug exposure than oral sumatriptan. Additional analyses of data from the Phase III trials show that significantly more patients with migraine receiving AVP-825 reported clinically meaningful relief, sustained relief, pain freedom, lower migraine-related disability and more consistent relief across multiple attacks than those receiving oral sumatriptan. The rapid and sustained action of AVP-825 and its convenience creates the potential for this unique treatment to reduce the burden of migraine in many patients.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/USN.2016.12.02.84

Disclosure: Deborah I Friedman is a consultant for Allergan, Avanir, Supernus, Teva Pharmaceuticals, Eli Lilly, Zosano, and Alder Biopharmaceuticals. She is a speaker for Avanir, Supernus, Teva Pharmaceuticals and has received research support from Merck, Autonomic Technologies, Inc., and Eli Lilly.

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes

US Neurology, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:
Carla Denaro - Managing Editor
managingeditor@touchmedicalmedia.com
Providing practical opinion to support best practice for busy healthcare professionals


'/>"/>
SOURCE touchNEUROLOGY.com
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Insomnia Pipeline Landscape and Therapeutics Development Market Review H2 2016
2. Viral Conjunctivitis Pipeline Drugs Market: (FST-100 and APD-209): Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023
3. Degenerative Scoliosis Global Clinical Trials Review, H2, 2016
4. Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
5. World Heart Federation Previews Global Roadmap to Tackle Cholesterol
6. Novel Intraocular Pressure-Lowering Agent, Latanoprostene Bunod, Under Review
7. Emmaus New Drug Application for Sickle Cell Disease Accepted for Review by FDA
8. Biotechnology Stocks Under Review - Eleven Biotherapeutics, Relypsa, Galena Biopharma, and Amgen
9. Market of Rett Syndrome Pipeline Reviewed of 14 Companies and 23 Drug Profiles
10. A New Review Defines Essential Components of Comprehensive Care of Patients With Spastic Paresis and the Need for a Long-Term Commitment
11. New Expert Review of Adaptive Servo-Ventilation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2018)... ... 29, 2018 , ... More than 205,000 individuals have signed the 4th Annual ... significantly increase funding for type 1 diabetes cure research after spending on such initiatives ... An estimated two million Americans are affected by type 1 diabetes, and about half ...
(Date:11/28/2018)... N.Y. (PRWEB) , ... November 28, 2018 , ... Satin ... presented a donation of $2,400 to Hudson Valley Honor Flight on Sept 28th, 2018 ... recent sales incentive campaign and presented to HVHF by Kevin O’Reilly, Founder and CEO ...
(Date:11/28/2018)... WOODLANDS, Texas (PRWEB) , ... November 28, 2018 ... ... from Rigaku Corporation has been published and is available to view ... concentrating on single crystal X-ray diffraction, published by Rigaku Oxford Diffraction , ...
Breaking Medicine Technology:
(Date:12/8/2018)... ... 2018 , ... Caring.com, the nation’s most visited website for senior living reviews, ... to its list of top medical alert systems for 2019. The medical alert provider ... one of fourteen companies that qualified for the list based on its demonstration of ...
(Date:12/6/2018)... SAN DIEGO (PRWEB) , ... December 06, 2018 ... ... alongside Mike Wilson, Medicare Analytic Consultant Senior of Blue Cross and Blue Shield ... Measures are Interrelated” on Tuesday, December 11, 2018 at 2:15pm PT at the ...
(Date:12/5/2018)... , ... December 05, 2018 ... ... advancing patient and family engagement with the use of the Precision Virtual ... technology provides Children’s National’s world-renowned neurosurgeons and physicians with a never-before view ...
(Date:12/5/2018)... , ... December 05, 2018 , ... Since PermaLip™ ... ruptures. The implants are invisible to the naked eye, ensuring a natural look. “I ... and that there are no signs of implant visibility,” says Dr. Jessica Kulak, double ...
(Date:12/5/2018)... ... , ... You can now experience two cutting edge Oregon brands at the ... in the cannabis industry with several brands including Sticks and Cabana ... award winning , botanical terpene company that focuses on using terpenes from non-cannabis sources ...
Breaking Medicine News(10 mins):